Zinzino Holding
Zinzino is a Swedish direct-sales company that sells health and skincare products through an independent distributor network and its own webshop. The group also includes Faun Pharma AS, a Norwegian contract manufacturer that produces food supplements for external customers.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueNutritional and wellness products sold mainly through the Zinzino webshop and distributors.
Skinserum and acquired skincare brands sold through the same direct-sales channel.
External contract manufacturing of food supplements for third-party customers.
Event sales, coffee, freight, reminder fees, and other ancillary income.
Customers
Zinzino sells primarily to end consumers who buy wellness products through recurring subscriptions, often supported by independent distributors and partners. It also serves distributors who use the platform, marketing tools, and events to build local customer networks, while Faun Pharma sells contract production services to external business customers.
Buy recurring health products through the webshop because the model is convenient and repeatable
Use Zinzino's tools, content, and product line to recruit and retain customers
Buy Skinserum and HANZZ+HEIDII products through the same direct-sales channel
Third-party food-supplement customers that source production from Faun Pharma
Buy event-related services and products tied to distributor meetings
Strategy
Zinzino's strategy centers on profitable growth through digital sales tools, distributor support, and expansion into new markets. It also uses acquisitions and partnerships to add distribution capacity, products, and production capabilities, while investing in IT, marketing, customer support, and logistics.
A stronger webshop and sales platform supports distributor productivity and customer conversion
New countries broaden the customer base and reduce dependence on mature markets
Acquisitions add distributor databases, IP, inventory, and production capacity
Owning more of the production chain improves product availability and development control
Geography
Zinzino is headquartered in Gothenburg, Sweden, and sells through a global webshop with coverage in more than 100 countries. Its business is built around local distributor networks, so market expansion depends on country-by-country compliance, language adaptation, and the ability to build sales organizations in new regions.
Risks
Zinzino's main risks come from rapid international expansion, dependence on distributor performance, and the need to comply with local rules in many markets. The business is also exposed to raw-material availability, currency swings, IT system complexity, and acquisition integration risk, all of which can affect sales execution and reported results.
- Distributor network dependenceImpact: HighLikelihood: Medium
Sales are driven through independent distributors and partners, so weak recruitment or retention can slow growth
Exposure: Global direct-sales model
- Raw-material and supply disruptionImpact: HighLikelihood: Medium
Health products depend on steady access to ingredients and production capacity
Exposure: Food supplements and skincare supply chain
- Acquisition integrationImpact: HighLikelihood: Low
Purchased distributor databases, inventory, and IP must be integrated without disrupting sales
Exposure - Regulatory compliance in new marketsImpact: High
Each country has its own tax, product registration, and consumer-law requirements
Exposure: International expansion
- Foreign exchange volatilityImpact: MediumLikelihood: Low
Revenue and costs are generated in multiple currencies across many markets
Exposure: Global operations
- IT and systems complexityImpact: MediumLikelihood: Low
Webshop, distributor tools, and market-specific systems must function reliably at scale
Exposure: Digital sales platform
Accounting
Judgemental itemsGoods are recognized when delivered, so cut-off timing affects quarterly revenue and comparability
Impact: Subscription orders and webshop shipments
Bonus points earned by subscription customers defer part of revenue until redemption
Impact: Reported revenue and deferred income
Acquisition earn-outs are measured using management estimates of future sales
Impact: Purchase accounting and liabilities
Acquisitions create goodwill and identifiable intangibles that must be tested for impairment
Impact: Balance sheet carrying values and future charges
Databases and licenses are amortized over estimated lives, affecting earnings over time
Impact: Amortization expense
Similar listed companies
Publicly listed companies with a comparable business focus.
Zivo Bioscience, Inc.
ZIVO · Biological Products, (No Diagnostic Substances)
USANA Health Sciences, Inc
USNA · Medicinal Chemicals & Botanical Products
USANA Health Sciences is a U.S.-based developer and manufacturer of nutritional supplements, personal care products, and skincare products sold internationally through direct selling.
Nu Skin Enterprises, Inc
NUS · Wholesale-Drugs, Proprietaries & Druggists' Sundries
LENZ Therapeutics, Inc.
LENZ · Biological Products, (No Diagnostic Substances)
LENZ Therapeutics is a U.S.-based pre-commercial biopharmaceutical company focused on developing and commercializing VIZZ, an aceclidine-based eye drop for presbyopia.
FitLife Brands, Inc
FTLF · Medicinal Chemicals & Botanical Products
Nature's Sunshine Products, Inc
NATR · Pharmaceutical Preparations
Nature’s Sunshine Products is a U.S.-based natural health and wellness company that manufactures and sells nutritional supplements and personal care products.
Last updated: 24/09/2026